NCT04662892View on ClinicalTrials.gov

An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca

UnknownOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

November 1, 2022

Study Completion Date

December 15, 2022

Conditions
Febrile NeutropeniaNon-myeloid Malignancy
Interventions
DRUG

Pegfilgrastim-Cbqv

Date, Dose, and cycle for subjects who received Udenyca will be recorded. Other FN prophylaxis such as Neulasta, or other pegfilgrastim biosimilars will be collected.

Trial Locations (3)

10320

RECRUITING

Southern Oncology Specialists, Charlotte

29572

RECRUITING

Coastal Cancer Center, Myrtle Beach

29732

RECRUITING

Carolina Blood and Cancer Care, PA, Rock Hill

Sponsors
All Listed Sponsors
collaborator

Community Clinical Oncology Research Network, LLC

UNKNOWN

lead

Coherus Oncology, Inc.

INDUSTRY

NCT04662892 - An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca | Biotech Hunter | Biotech Hunter